AstraZeneca Pharma India Limited has successfully concluded its postal ballot process and declared the voting results for material related party transactions. The company announced on March 31, 2026, that both ordinary resolutions seeking approval for transactions with related entities have been passed by the requisite majority of non-related members.

Postal Ballot Overview

The postal ballot was conducted with a record date of February 20, 2026, covering 29,857 total shareholders on record. The voting process was entirely electronic, conducted through the National Securities Depository Limited (NSDL) platform from February 28, 2026, to March 29, 2026.

Resolution Results

Both resolutions related to material related party transactions received strong support from non-related shareholders. The first resolution for transactions with AstraZeneca UK Limited and the second for transactions with AstraZeneca AB, Sweden both achieved similar voting patterns.

Resolution 1: AstraZeneca UK Limited Transactions

Resolution 2: AstraZeneca AB Sweden Transactions

Voting Participation and Process

A total of 297 members participated in the electronic voting process. The promoter and promoter group, holding 18,750,000 shares, abstained from voting as they were interested parties in both resolutions. The voting process was supervised by Mr. Vijayakrishna K.T, a practicing Company Secretary, who served as the scrutinizer.

The postal ballot notice was distributed electronically in compliance with MCA circulars, eliminating the need for physical ballot forms. Invalid votes were recorded across categories, with 13,850 invalid votes from public institutions and 2,141 from public non-institutions for both resolutions.

Regulatory Compliance

The postal ballot was conducted in accordance with Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The voting results and scrutinizer's report have been made available on the company's website and NSDL's e-voting platform. The company has informed both BSE Limited and National Stock Exchange of India Limited about the successful passage of both resolutions, ensuring full regulatory compliance for the material related party transactions.

AstraZeneca Pharma India Limited has announced the resignation of Mr. Jesús Diaz-Ropero Esteso from his position as Non-Executive Director, effective immediately. The pharmaceutical company informed both BSE Limited and National Stock Exchange of India Limited about this board change on March 20, 2026, in compliance with regulatory disclosure requirements.

Board Transition Details

The resignation became effective on March 19, 2026, with Mr. Esteso citing a transition from current responsibilities as the reason for his departure. Along with stepping down from his directorship, he has also resigned from all Board Committees on which he served.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The formal intimation was signed by Company Secretary & Compliance Officer Tanya Sanish and submitted to both stock exchanges with the required documentation.

The filing included comprehensive annexures detailing the cessation particulars and a copy of the original resignation letter dated March 19, 2026. The resignation letter was brief, stating the director's decision to step down with immediate effect due to his transition from current responsibilities.

Documentation Process

AstraZeneca Pharma India Limited has provided all necessary documentation as per SEBI Master Circular requirements. The company requested both exchanges to take the intimation on record, ensuring full transparency regarding the board composition change.

The resignation represents a routine corporate governance matter, with the company maintaining proper disclosure protocols throughout the transition process.